Skip to content
Screener

Corcept Therapeutics CORT Q1 2025 earnings

Reported May 5, 2025 · After market close

Revenue$157.2MMiss by $59.5M
EPS$0.17In line
Revenue estimate$216.7M
EPS estimate$0.17

Next report

Nov 4, 2026 (in a month)
Revenue estimate$323.9M
EPS estimate$0.81

Financials

Q1 2025

Income statement

See full
Revenue$157.2M+7.1%
Gross profit$154.8M+7.3%
Operating income$3.4M-88.4%
Net income$20.5M-26.0%
EPS (diluted)$0.17-32.0%

Balance sheet

See full
Cash & equivalents$89.8M-40.0%
Total debt$6.8M+8,893%
Total equity$683.3M+24.7%
Total assets$846.5M+29.0%

Cash flow

See full
Operating cash flow$5.1M-78.4%
CapEx$104.0K—
Free cash flow$5.0M-78.9%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$12.05B+362%
Enterprise value$11.97B+387%
P/E89.9×+67.8×
P/S17.6×+12.6×

Profitability

See full
Gross margin98.4%-0.1pp
Operating margin16.2%-7.1pp
Net margin19.5%-3.0pp
FCF margin25.8%+2.0pp

Returns & leverage

See full
Return on equity21.8%-0.1pp
Debt / equity0×0.0×
Current ratio3.1×-2.1×

FAQ

When did Corcept Therapeutics report Q1 2025 earnings?
Corcept Therapeutics (CORT) reported Q1 2025 earnings on May 5, 2025 after market close.
What were Corcept Therapeutics's Q1 2025 revenue and EPS?
Corcept Therapeutics reported revenue of $157.2M and eps of $0.17 for Q1 2025.
Did Corcept Therapeutics beat estimates in Q1 2025?
Revenue missed the consensus estimate of $216.7M by $59.5M. EPS beat the consensus estimate of $0.17 by $0.00.
How did Corcept Therapeutics's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 7.1% from $146.8M a year earlier and eps declined 32.0% from $0.25.
Where can I find Corcept Therapeutics's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001628280-25-022167) and the 10-Q periodic report (0001628280-25-022173) directly on SEC EDGAR. The filing index links above go to sec.gov.